RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on October 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018. The top-line results shows that the vast majority of...
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference
SHELTON, Conn., Oct. 5, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, presented an update of its Pan-Coronavirus COVID-19 Drug Development Program at the Benzinga Healthcare Small Cap Conference on September 30, 2021 at 10:10am EST....
Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at three dosage levels. Assessment with Pharmaxis' proprietary assays of the highest dose...
New clinical trial shows 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube
STOCKHOLM, Oct. 5, 2021 /PRNewswire/ -- This week at the European Society of Intensive Care congress (ESICM), a study from Liège, Belgium on Bactiguard's endotracheal tubes was presented. The study showed a 53% reduction in ventilator-associated pneumonia (VAP) in intensive care patients, intubated with Bactiguard's endotracheal tube with evacuation lumen (BIP ETT Evac). "These data are of vital importance...
New, Unpublished Data Reveals Impact of COVID-19 in Patients With Neurological Disorders; Renowned Neuroscientist Ettore Beghi Presents Findings in “Special Lecture on Neuro COVID,” Oct 4, 2021, World Congress...
LONDON, Oct. 5, 2021 /PRNewswire/ -- New data for the first time reveals a connection between COVID-19 and its worsening impact on patients with existing neurological conditions. Newly released research identifying distinct profiles of COVID-19 patients with neurological conditions and manifestations was unveiled at the 25th Biennial World Congress of Neurology (WCN) 2021 by world-renowned researcher Ettore Beghi, professor of...
Mars Pledges Fresh Climate Action to Achieve Net Zero Emissions Across Full Value Chain
The company sets new science-based climate target to achieve net zero greenhouse gas (GHG) emissions across its full value chain by 2050, including all scope 3 emissions (as defined by SBTi) such as those created by agriculture and suppliers, through to emissions from consumers using its iconic household brands such as Ben's Originals, M&M's & Royal Canin. ...
Dr Joshua Loh Shares New and Advanced Percutaneous Coronary Intervention (PCI) Techniques in 2021 to Treat Coronary Heart Disease – a Major Cause of Death in Singapore
SINGAPORE, Oct. 5, 2021 /PRNewswire/ -- According to the Ministry of Health Singapore, coronary heart disease accounted for 20.5% of all deaths in Singapore in 2020. In this article, Dr Joshua Loh, Senior Consultant Interventional Cardiologist from Capital Heart Centre, shares the techniques of Percutaneous Coronary Intervention (PCI) to treat coronary heart disease and how they have advanced over the years. ...
Zuellig Pharma Receives EcoVadis Platinum Medal in 2021 For Sustainability
SINGAPORE, Oct. 5, 2021 /PRNewswire/ -- Zuellig Pharma, a leading healthcare services provider in Asia, has been awarded the Platinum Medal 2021 by sustainability ratings specialist EcoVadis. The award is the highest accolade to be awarded to a company for its sustainability efforts and positions Zuellig Pharma in the top 1% of all assessed companies worldwide. This award also places...
GenScript establishes Korean legal entity and accelerates sales activities
SEOUL, South Korea, Oct. 5, 2021 /PRNewswire/ -- GenScript, a global biotech company, recently completed the establishment of a legal entity called "GenScript Biotech Korea Ltd." and began to strengthen its sales activities in Korea in earnest. GenScript Biotech Korea Ltd. has built a nest at IKP (Invest Korea Plaza) in Heolleung-ro, Seocho-gu, Seoul. The main purpose of the establishment...
Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC
SHANGHAI and SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced that it has submitted four investigational new drug (IND) applications...
